Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Cardium Therapeutics, Inc. (CXM) Subsidiary Enters Commercialization Agreement for Life Insurance Products

Cardium Therapeutics recently announced that its wholly-owned subsidiary, LifeAgain™ Insurance Solutions Inc., has entered into a commercialization agreement with AgencyONE. The agreement will have LifeAgain™ supporting the development and commercialization of innovative, survivable risk life insurance products based on Cardium’s advanced medical data analytics platform technology (ADAPT™).

Developed by Cardium researchers, LifeAgain is a newly-formed medical data analytics business that’s focused on the development, marketing and sale of survivable risk term life insurance programs. The programs are designed to help patients with certain cancers or other medical conditions who are typically considered uninsurable based on traditional life insurance underwriting standards.

LifeAgain’s initial product platform will be centered on Cardium’s BlueMetric Select™ term life insurance program, which has been specifically designed for men with active localized prostate cancer. Employing Cardium’s advanced medical data analytics, this pioneering program is the first and only product offering specifically developed for cancer patients based on risk assessments.

Working in cooperation with large and established life insurance companies, LifeAgain uses its proprietary medical data analytics technology to apply medically-driven algorithms and other quantitative tools to broaden eligibility for individuals with specific medical conditions. The technology can also assess individualized mortality using the prognostic value of advanced medical diagnostic information that’s supported by long-term clinical studies, peer-reviewed publications, and physician consensus. What’s more, LifeAgain can use its innovative solution to establish customized policy premium pricing in a cost-effective and scalable manner. All its efforts operate within the life insurance industry’s established underwriting practices and standard operating procedures.

For more information, visit www.cardiumthx.com/lifeagain

Let us hear your thoughts below:

This entry was posted in Cardium Therapeutics Inc. CXM. Bookmark the permalink.

Comments are closed.